Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Urtė Fultinavičiūtė

Reporter

London, UK

Urtė has previously worked as a Healthcare Reporter at GlobalData Media, primarily writing for Clinical Trials Arena. She mostly focused on clinical trial data management, strategy, and regulatory updates as well as clinical trial data readouts and exclusive interviews with C-level pharma and biotech executives. Urtė holds an MA in International Journalism from City, University of London.

Latest From Urtė Fultinavičiūtė

Lupin And Zentiva Snatch First Generic Raltegravir Approval In UK

The UK’s MHRA has approved the first generic raltegravir to treat HIV in adults and certain pediatric patients and deemed the drug interchangeable with the originator Isentress.

Generic Drugs Launches

Endo En Route To NYSE With Common Stock Exchange Expected Later In 2024

Endo continues to stride its financial revival path, with the latest plans to list common stock on the NYSE. Also, the firm has just launched a generic tiopronin rival to Travere Therapeutics' Thiola.

Financing Strategy

Off-Patent Group Trio Aims To Secure Transatlantic Drug Supply

Three off-patent associations from both sides of the Atlantic want to strengthen their collaborative synergies and secure the supply of generics and biosimilars.

Generic Drugs Supply Chain

Off-Patent Group Trio Aims To Secure Transatlantic Drug Supply

Three off-patent associations from both sides of the Atlantic want to strengthen their collaborative synergies, securing the supply of generics and biosimilars.

Policy Regulation

Regulatory Recap: US Senate Passes Anti-Patent Thicket Bill, EU Council Debates Pharma Package

Generics Bulletin recaps the most recent regulatory news and updates from across the world.

Regulation Generic Drugs

AI And Biosimilars: Untapped Area Full Of Potential – Or Hype?

AI could help biosimilar developers with the development and manufacture of their products, but dependence on high-quality training datasets poses potential challenges.

Biosimilars Artificial Intelligence
See All
UsernamePublicRestriction

Register